康泰医学的前世今生：2025年Q3营收3.44亿低于行业均值，净利润939.98万排名靠后

Core Viewpoint - 康泰医学 is a leading domestic medical device manufacturer focused on the research, development, and production of medical diagnostic and monitoring equipment, with strong technical capabilities [1] Financial Performance - In Q3 2025, 康泰医学 reported revenue of 344 million yuan, ranking 29th out of 42 in the industry, significantly lower than the top competitor,迈瑞医疗, which had revenue of 25.83 billion yuan, and the second competitor,联影医疗, with 8.86 billion yuan [2] - The net profit for the same period was 9.40 million yuan, ranking 31st in the industry, again showing a substantial gap compared to 迈瑞医疗's net profit of 7.81 billion yuan and 鱼跃医疗's 1.47 billion yuan [2] Financial Ratios - As of Q3 2025, 康泰医学's debt-to-asset ratio was 36.72%, an increase from 31.74% in the previous year, which is higher than the industry average of 27.21%, indicating increased debt pressure [3] - The gross profit margin for Q3 2025 was 54.73%, up from 49.90% year-on-year, and above the industry average of 48.67%, reflecting strong profitability [3] Executive Compensation - The chairman, 胡坤, received a salary of 425,100 yuan in 2024, a decrease of 24,100 yuan from 2023 [4] - The general manager, 杨志山, had a salary of 325,400 yuan in 2024, down by 80,200 yuan from the previous year [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 11.54% to 34,700, with an average holding of 7,308.85 shares, a decrease of 10.35% [5] - The top ten circulating shareholders included new entrants such as 大成景恒混合A and 医疗器械ETF, with holdings of 1 million shares and 989,900 shares respectively [5]